AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 ( K D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation In Vivo AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis . AMY-101 can induce a long-lasting anti-inflammatory effect . AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction . AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight) . Dosage: 0.1 mg/site; 50 μL of 2 mg/mL solution. Administration: Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.) Result: Does not cause irritation in healthy gingiva. Animal Model: UUO and sham-operated mice. Dosage: 1 mg/kg. Administration: Subcutaneous injection every 12 h, daily, 7 or 14 days. Result: 1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice. Form:Solid IC50& Target:KD: 0.5 nM (C3)